Bridging Autism and Parkinson’s: How One Family’s Search for Answers Led to a Rare Genetic Discovery

The pursuit of a medical diagnosis can often feel like navigating an endless labyrinth, particularly when dealing with rare pediatric neurodevelopmental conditions. For Jennifer and Dr. Peter Johnson of Houston, the journey to understand their son Owen’s complex symptoms spanned nearly a decade. What began as delayed speech milestones in a toddler ultimately converged with cutting-edge artificial intelligence, Parkinson’s disease research, and a rare genetic mutation known as ITSN1. Their story highlights the profound intersection between clinical persistence and molecular genetics, offering a glimpse into how modern science is beginning to decode some of the brain’s most well-kept secrets.

The Early Years: Noticing the Divergence

Owen Johnson’s early development initially mirrored that of any typical toddler. Born alongside his twin sister Alice—part of a bustling household that also included older twin sisters Audrey and Evelyn—Owen was described by his mother as a happy and energetic child. However, subtle signs began to emerge during his preschool years in Houston. Owen took longer than expected to acquire speech and exhibited intense fixations, such as an overwhelming obsession with the color red.

While his parents initially attributed these behaviors to normal developmental variations, a widening gap soon became apparent between Owen and his twin sister. He struggled to connect with peers, and his teachers at preschool were surprised when informed of an eventual autism diagnosis at age 3. Standard pediatric interventions, including early behavioral and speech therapies, offered temporary relief. Yet, as Owen grew, his vibrant disposition began to shift. He grew increasingly withdrawn, moody, and uncommunicative. Activities he once loved, such as singing in the annual Mother’s Day performance with his siblings, fell by the wayside as his ability to focus in school deteriorated.

Driven by an intuitive parental instinct, the Johnsons suspected that a standard autism diagnosis did not fully encompass the breadth and progression of Owen’s symptoms. Without alternative explanations, however, they were compelled to rely solely on incremental adjustments to his therapy regimens and medications.

A Timeline of Discovery: From Routine Testing to AI-Driven Genomics

The quest for a definitive medical answer unfolded over several distinct milestones:

• 2021: Seeking a deeper understanding of Owen’s condition, his pediatric care team ordered a blood sample for genetic testing. The initial results returned blank, providing no novel insights or actionable genetic markers to explain his cognitive and behavioral regression.
• Mid-2022: A year after the initial genetic screen, Jennifer Johnson received an unexpected email notification from the testing laboratory. New clinical research had emerged identifying variants in the ITSN1 gene as "likely pathogenic," linking them directly to neurodevelopmental disorders that mimic autism.
• 2023: The Johnsons consulted pediatric neurologist Dr. Sarah Risen at Texas Children’s Hospital. Dr. Risen ordered follow-up genetic testing that officially confirmed the presence of the ITSN1 variant and adjusted Owen’s pharmacotherapy to better address his specific symptom profile.
• Early 2025: Dr. Risen connected the Johnson family with Dr. Ryan Dhindsa, a principal investigator at the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital and assistant professor at Baylor College of Medicine, who was actively studying the ITSN1 mutation as part of broader Parkinson’s disease research.
• Present: Owen, now 10 years old, participates as part of a small cohort of roughly 20 families collaborating with Dr. Dhindsa’s laboratory on a natural history study tracking the progression of ITSN1-related syndrome.

Unraveling the ITSN1 Mutation: The Parkinson’s and Autism Connection

While the Johnson family was grappling with uncertainty in Houston, Dr. Dhindsa and his research team were utilizing advanced computational biology to examine the genetic architecture of Parkinson’s disease. Every human child is born with approximately 70 spontaneous de novo genetic mutations that are not inherited from either parent. While the vast majority of these variants are harmless, rare statistical anomalies can cause a mutation to disrupt a critical gene.

To isolate these needles in a genomic haystack—given that the human genome comprises over 3 billion base pairs of DNA—Dr. Dhindsa’s lab deployed artificial intelligence algorithms to sequence and analyze genomic data from approximately 800,000 individuals, comparing cohorts with Parkinson’s disease against healthy controls.

The computational analysis revealed a striking correlation: many patients with Parkinson’s disease carried mutations in the ITSN1 gene, which encodes a protein vital for facilitating efficient communication between brain cells. Subsequent laboratory investigations demonstrated that individuals harboring an ITSN1 variant face a risk factor up to 10 times higher for developing Parkinson’s disease later in life.

Intriguingly, as the genomic database expanded, the researchers observed a parallel trend. ITSN1 variants were disproportionately represented in pediatric patient populations diagnosed with autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD). This overlapping genetic vulnerability bridges two seemingly disparate neurological conditions: early-onset developmental disorders and late-onset neurodegenerative disease.

Clinical Challenges and Diagnostic Complexity

The clinical manifestation of ITSN1-related syndrome remains deeply perplexing to the medical community. Present in an estimated one in 5,000 individuals, the mutation is characterized by significant penetrance anomalies. According to Dr. Dhindsa, approximately 60% of patients who inherit the variant from a parent find that the transmitting parent remains entirely unaffected, displaying no clinical symptoms of either neurodevelopmental delays or Parkinson’s disease.

This unpredictability complicates clinical management. Children who present with the ITSN1 variant are frequently channeled through diagnostic pathways for autism and ADHD. Conversely, adults who manifest Parkinson’s disease linked to ITSN1 typically report no prior history of childhood neurodevelopmental disorders. Such clinical paradoxes underscore why specialized research institutions are essential for mapping the nuanced pathways of rare genetic variants.

Dr. Huda Zoghbi, a renowned neurogeneticist and founding director of the Duncan NRI, emphasizes that genes serve as fundamental entry points for decoding how neural networks fail or succumb to degradation over time. "Once you know that," Dr. Zoghbi noted, "we can then begin to say, ‘How do you reverse it?’"

Inside the Laboratory: Advanced Modeling and Stem Cell Research

At the Duncan NRI, researchers are deploying state-of-the-art methodologies to decode the functional consequences of the ITSN1 variant. Because human brain tissue is largely inaccessible for direct study in living patients, Dr. Dhindsa’s laboratory undertook an intricate 18-month cellular reprogramming protocol using skin cell samples provided by Owen Johnson.

The lab successfully reprogrammed Owen’s somatic skin cells into induced pluripotent stem cells (iPSCs), which were subsequently differentiated into specialized brain cell lineages—some engineered to carry the ITSN1 variant and others serving as control cells without the mutation. This cellular model allows researchers to observe real-time functional deficits in neuronal communication and synaptic plasticity.

Simultaneously, the research team is utilizing murine (mouse) models to track the longitudinal impact of the ITSN1 variant across a full lifespan. By monitoring learning curves, memory retention, and cognitive performance in mice, scientists hope to isolate the precise physiological triggers that shift a carrier from an asymptomatic state toward either neurodevelopmental impairment in youth or neurodegeneration in adulthood.

Broader Implications for Rare Disease Research and Patient Advocacy

The integration of families into active clinical research is a cornerstone of modern translational medicine, particularly in the realm of ultra-rare diseases. Dr. Zoghbi points out that while genetic discoveries provide immediate psychological relief by validating a family’s long-held suspicions, the subsequent realization of how arduous therapeutic development can be requires transparent, empathetic partnerships between scientists and patient advocates.

"We give them hope, but we also take them along with us on the journey," Dr. Zoghbi explained. "They know we’re doing all the steps, one by one, and as fast as we can."

For the Johnson family, this collaborative approach has transformed an isolating medical mystery into a shared endeavor. Although the spectrum of ITSN1-related outcomes ranges widely—from mild learning disabilities and ADHD to severe language regression and adult-onset movement disorders—proactive intervention has yielded measurable improvements for Owen.

Now 10 years old, Owen has embraced new interests, such as a fascination with dinosaurs and playing tag with his siblings. Recent pharmacological adjustments have optimized his mood and concentration, while his current school environment in Tomball integrates specialized therapeutic support directly into his daily classroom schedule.

While Owen will likely require lifelong support, breakthroughs at research facilities like the Duncan NRI foster cautious optimism among families affected by rare genetic variants. The ultimate objective remains clear: to develop targeted pharmacotherapies that halt cognitive regression and preserve neurological function, transforming theoretical genetics into tangible clinical healing.